Long-term survival of patients with resistant lymphoma treated with tandem stem cell transplant

Leukemia and Lymphoma

Volumn 46, Issue 3, 2005, Pages 405-414

  Ahmed, Tauseef ^a,b   Rashid, K ^a   Waheed, F ^a   Kancherla, R ^a   Qureshi, Z ^a   Hoang, A ^a   Richter, J ^a   Ali, M F ^a   Goldberg, R ^a   Liu, D ^a   Seiter, K ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NONE   (United States)

Author keywords

Mitoxantrone; Refractory lymphoma; Tandem transplant

Indexed keywords

ACICLOVIR; CARBOPLATIN; ETOPOSIDE; FLUCONAZOLE; IFOSFAMIDE; MITOXANTRONE; NARCOTIC ANALGESIC AGENT; THIOTEPA;

ADULT; AGE; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLADDER DISEASE; BLEEDING; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DRUG FATALITY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 20844443273     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190400019826     Document Type: Article

References (39)

1. De Vita VT, Simon RM, Hubbard SM et al. Curability of advanced Hodgkin's disease with chemotherapy. Ann Int Med 1980;92:587-595.
2. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease (see comments). N Engl J Med 1998;339:1506-1514.
3. Straus DJ, Gaynor JJ, Myers J et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating non cross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 8:1173-1186.
4. Santoro A, Viviana S, Villareal CJ. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 1986;70(3):343-348.
5. Linch D, Winfield D, Goldstone A et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of BNLI randomized trial. Lancet 1993;341:1051-105.
6. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des Lymphomes de I'Adulte study. J Clin Oncol 2000;18:3025-3030.
7. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
8. Yu J, Leisenring W, Bensinger WI, Holmberg LA, Rowley SD et al. The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield. Transfusion 1999;39(5):442-450.
9. Stiff PJ, Koester AR, Weidner MK, Dvorak K, Fisher RI et al. Autologous bone marrow transplantation using unfractionated cells cryopreserved in imethylsulfoxide and hydroxyethyl starch without controlled-rate freezing. Blood 1987;70:974-978.
10. Common Toxicity Criteria, NCI, 1999.
11. Lazarus HM, Rowlings PA, Zhang MJ et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999;17:3101-3109.
12. Sweetenham JW, Santini G, Qian W et al. High-dose therapy and autologous stem-cell transplantation vs conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Working Party. J Clin Oncol 1999;17:3101-3109.
13. Attal M, Harousseau JL, Facon T et al., the InterGroupe Francophone du Myélome. Single vs double autologuos stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502.
14. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
15. De Lima M, van Besien KW, Giralt SA et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 1997;19: 121-127.
16. Vandenberghe E, Pearce R, Taghipour G, Goldstone A et al. Two autotransplants for lymphoma - acceptable toxicity (18%) of the second transplant and significant survival length in some patients. Data from the EBMT lymphoma registry. Blood 1995;86:971 (abstract 3871).
17. Fitoussi O, Simon D, Brice P et al. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 1999;24:747-755.
18. Philip T, Bouabdallah R, Brice P et al. Phase II study testing a double intensification in aggressive non-Hodgkin's lymphoma relapsing less than one year after initial treatment (PARMA2 study). Bone Marrow Transplant 2000;25 (Suppl. 1):S180 (abstract P559).
19. Ballestrero A, Clavio M, Ferrando F et al. High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma. Int J Oncol 2000;17:1007-1013.
20. Brice P, Divine M, Simon D et al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. Ann Oncol 1999;10:1485-1488.
21. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Coady-Lyons N, Straus DS et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17(12):3776-3785.
22. Metayer C, Curtis RE, Vose J et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003;101:2015-2022.
23. Aleman BM, Raemaekers JM, Tirelli U et al. European Organization for Research and Treatment of Cancer Lymphoma Group. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003;348(24):2396-2406.
24. Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, Naresh KN, Dinshaw KA. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22(1):62-68.
25. Pezner RD, Nademanee A, Forman SJ. High-dose therapy and autologous bone marrow transplantation for Hodgkin's disease patients with relapses potentially treatable by radical radiation therapy. Int J Radiat Oncol Biol Phys 1995;33(1): 189-194.
26. Pezner RD, Nademanee A, Forman SJ et al. Evidence of a graft-versus- lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991;77:649-653.
27. Anderson J, Litzow M, Appelbaum F et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21 year Seattle experience. J Clin Oncol 1993;11:2342-2350.
28. Khouri IF, Keating M, Körbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies (see comments). J Clin Oncol 1998;6:2817-2824.
29. Khouri IF, Giralat S, Saliba R et al. "Mini"-allogeneic stem cell transplantation for relapsed/refractory lymphomas with aggressive histologies. Proc Am Soc Clin Oncol 2000;19:47a.
30. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hematopoietic stem cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18:3918-3924.
31. Dazzi F, Szydlo RM, Craddock C et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000;95:67-71.
32. Alyea E, Soiffer R, Canning C et al. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91:3671-3680.
33. Waller EK, Boyer M. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells. Bone Marrow Transplant 2000;25:S20-S24.
34. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-1724.
35. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754-2759.
36. Porter D, Bunin N, Laport G et al. Graft-vs-tumor induction with donor leukocyte infusions expanded ex vivo by activation with CD3/CD28 costimulation. Blood 2001;98:404a.
37. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995;345:1016-1020.
38. Bollard CM, Rossig C, Calonge MJ et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002;99: 3179-3187.
39. Hartmann F, Renner C, Jung W et al. Anti-cd16/cd30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 2001;7:1873-1881.